BridgeMD
A study to assess efficacy and safety of empasiprubart versus IVIg in adults with CIDP ("emvigorate")
EU CTIS ID: 2024-520097-36-00
What this study is testing
To demonstrate the efficacy of empasiprubart IV compared with IVIg in improving functional ability
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Meets criteria for CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
- 2. Has either typical CIDP or 1 of the following CIDP variants: motor CIDP, multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP.
- 3. Has responded to IVIg in the past 5 years.
- 4. Receiving treatment with IVIg within a standard optimal maintenance dosing regimen, with a minimum weekly IVIg dose of at least 0.125 g/kg
- 5. Has residual disability and active disease
You likely can't join if
- 1. Meets the criteria for possible or sensory CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
- 2. Besides the indication under study, known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of CIDP or puts the participant at undue risk, including polyneuropathy of other causes
- 3. Use of other long-acting immunomodulatory treatment
The study team makes the final eligibility decision.
Where it's taking place
- Canada
- Switzerland
- Korea, Republic of
- Singapore
- Turkey
- Mexico
- Colombia
- United States
- Serbia
- Brazil
- Tunisia
- Australia
- Japan
- China
- Saudi Arabia
- Israel
- Argentina
- United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Canada; Switzerland; Korea, Republic of; Singapore; Turkey; Mexico and 12 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.